Catalyze Annual Meeting 2023 - Discovering Diverse Sources of Follow On Funding

Meeting description

Panel presentation by Dr. Jon Collins, Chief Scientific Officer, Pinnacle Hill, Dr. Stephanie Davis, Small Business (SBIR/STTR) Program Coordinator, NHLBI, NIH, Dr. Prabhavathi Fernandes, Chair, National Biodefense Science Board, ASPR, HHS, and Dr. David Winter, Program Officer, BARDA DRIVe, HHS

Jon L. Collins is a seasoned research and development executive with more than 20 years in the pharmaceuticals industry. He currently serves as chief scientific officer of Pinnacle Hill, LLC. Pinnacle Hill seeks to discover new medicines to address the significant unmet needs of our times, was developed through a partnership between the University of North Carolina at Chapel Hill and Deerfield Management, a health care investment firm. Prior to joining Pinnacle Hill Dr. Collins led drug discovery research teams at GlaxoSmithKline that focused on the scientific evaluation of novel protein targets, identification of clinical candidate molecules, and design of proof of concept clinical studies.

Stephanie M. Davis currently serves as the Small Business Program Coordinator at the National Heart, Lung, and Blood Institute. She graduated summa cum laude with her B.S. in Biochemistry and Molecular Biology from Florida Southern College. She received her M.S. in Medical Sciences and her Ph.D. in Molecular Pharmacology from the University of South Florida (USF), where she was a recipient of the Presidential Doctoral Fellowship from the USF Graduate School. She was a postdoctoral scholar at the University of Kentucky in the Department of Neurology. In addition to her postdoctoral appointment, Dr. Davis also interned with the UK Office of Technology Commercialization in 2019. Before joining the NHLBI Innovation Office, Dr. Davis was selected for the 2019-2020 Executive Branch AAAS Science and Technology Policy Fellows Program, where she served as a Program Manager in the National Institute on Aging Office of Small Business Research until December 2020.

Dr. David Winter is the Team Leader for both the BARDA Accelerator Network and the Blue Knight collaboration with JNJ Jabs. He earned his PhD at SUNY-Buffalo and spent 18 years at the bench at RPMI, Johns Hopkins University, NIH, and the Walter Reed Army Institute of Research before moving into Program Management at NIAID/NIH. Dr. Winter also served as the external collaborations manager for Novartis Vaccines and Diagnostics in Siena, Italy, before returning to NIH. He then served at the Center for Scientific Review running two study sections- the Cellular and Molecular Immunology A (CMI-A) study section and the Innovative Immunology SBIR/STTR special emphasis panel. In 2016, he was appointed as an Embassy Science Fellow for the State Department to work with the Indonesian government to design a national peer review system for science grants.

Moderated by Mr. James Redden, Innovation Advisor, RTI International

Jim has 10 years of industry and innovation experience, specializing in front-end-of-innovation strategy, including strategic foresight, trend-spotting and scenario planning, innovation process, opportunity identification, and strategic roadmapping. He has worked extensively at the intersection of innovation and emerging trends in intelligent systems (Artificial Intelligence, Machine Learning, IoT, etc.) and leads the RTI Innovation Advisors foresight practice. Jim leverages his prior teaching experience as one of the go-to advisors for projects involving capacity building, facilitating innovation workshops, design sprints, and innovation labs. His unique career path reflects his diverse interests and his desire to make the world a better place.

This meeting was recorded on September 21st, 2023.

This video is provided for educational purposes only.

This research was, in part, funded by the National Institutes of Health (NIH) Agreement OT2 HL157844-01. The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the NIH.